Specified Drug Use-Results Survey of Regnite

Status Completed

Clinical Trial Summary

This study is to investigate the long-term safety and efficacy and the information on the proper use of Regnite® under conditions of daily clinical use.

Clinical Trial Description

Sleeping condition and severity of restless legs syndrome (RLS) were recorded at the start and during the treatment. The treatment period is scheduled to last 52 weeks in principle. For patients completing or discontinuing the use of Regnite® within 52 weeks, follow up on the withdrawal and rebound syndrome will be conducted up to 4 weeks of completion or discontinuation. ;

Study Design

Related Conditions & MeSH terms

Restless Legs Syndrome

Clinical Trial Details

NCT number	NCT01887613
Study type	Observational
Source	Astellas Pharma Inc
Contact
Status	Completed
Phase
Start date	October 1, 2012
Completion date	February 28, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04786314` - The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome	N/A
Completed	`NCT01455012` - Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome	Phase 4
Terminated	`NCT01192503` - Safety and Efficacy of Rasagiline in Restless Legs Syndrome	Phase 2/Phase 3
Completed	`NCT00530530` - ASP8825 - Study in Patients With Restless Legs Syndrome	Phase 2
Completed	`NCT00721279` - Sifrol (Pramipexole) Onset of Action and Impact: a 12-weeks Observational Study in Patients With Primary Restless Legs Syndrome	N/A
Completed	`NCT00942253` - Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS)	Phase 2
Completed	`NCT00375284` - A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS	Phase 4
Completed	`NCT00479531` - Sequential Compression Devices for Treatment of Restless Legs Syndrome	Phase 3
Recruiting	`NCT05581576` - Pitolisant in Refractory Restless Legs Syndrome	Phase 4
Active, not recruiting	`NCT03218969` - Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist	Phase 1/Phase 2
Recruiting	`NCT04144790` - Impact of Iron Supplementation Treatment on Brain Iron Concentrations
Completed	`NCT05787080` - Massage, Oxidative and Antioxidant Enzymes in Hemodialysis Patients With Restless Legs Syndrome(RLS)	N/A
Not yet recruiting	`NCT05529095` - Sublingual Apomorphine in Refractory Restless Legs Syndrome	Phase 4
Recruiting	`NCT05044520` - Clinical Features Associated With Restless Legs Syndrome.
Withdrawn	`NCT03849001` - Impact of Acute Leg Cycling at Various Intensities on RLS Severity in Persons With MS	N/A
Completed	`NCT03076541` - Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements.	N/A
Recruiting	`NCT04145674` - A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo	Phase 2
Completed	`NCT02532608` - Infra-slow Oscillations During Sleep	N/A
Completed	`NCT01528462` - Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
Completed	`NCT00748098` - Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance	Phase 3